Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region

NCT04468165 is registered in ClinicalTrials.gov with Hikma Pharmaceuticals LLC as lead sponsor.

NCT NCT04468165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04468165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
Lead sponsor
Hikma Pharmaceuticals LLC
Phase
Observational
Overall status
Completed
Start date
February 23, 2021
Completion date
July 20, 2023
Enrollment
160 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis